Bolt Biotherapeutics Revenue
Biotechnology Research • 
Redwood City, California, United States • 51-100 Employees
Bolt Biotherapeutics revenue & valuation
| Annual revenue | $4,167,000 |
| Revenue per employee | $65,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $13,400,000 |
| Total funding | $15,000,000 |
Key Contacts at Bolt Biotherapeutics
Bert Qin
Director Of Finance
James Healy
Board Member, Lead Independent Director
Anh Nguyen
Director, Human Resources
Michael Alonso
Scientific Co-Founder & Senior Vice President, Research
Filip Petronijevic
Associate Director
Calvin Leung
Senior Director, Corporate Controller
Marie D.
Sr. Director, Translational Science Operations
Jason Ptacek
Director Of Translational Science And Biomarkers
Samara Violet
Senior Director, Project Management
Joseph Rebholz
Director, Clinical Data Management
Company overview
| Headquarters | 900 CHESAPEAKE DRIVE, REDWOOD CITY, California 94063, US |
| Phone number | +16506659295 |
| Website | |
| SIC | 283 |
| Founded | 2015 |
| Employees | 51-100 |
| Socials |
Bolt Biotherapeutics Email Formats
Bolt Biotherapeutics uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@boltbio.com), used 61% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@boltbio.com | 61% |
{first name}{last name} | johndoe@boltbio.com | 34.1% |
{last name}{last name} | doedoe@boltbio.com | 4.9% |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Bolt Biotherapeutics has 28 employees across 8 departments.
Departments
Number of employees
Bolt Biotherapeutics Tech Stack
Discover the technologies and tools that power Bolt Biotherapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Analytics
Video players
JavaScript libraries
Maps
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Advertising
Programming languages
Italy
Denmark
Saudi Arabia
Frequently asked questions
4.8
40,000 users
